Device Trial Radar · NCT06293430
Registry on Luma Vision's VERAFEYE System (ENLIgHT)
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Dec 15, 2027
Primary completion
Mar 15, 2028
Study completion Mar 15, 2028
Sponsor
- Lead sponsor
- LUMA Vision Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 5, 2024
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the study is to compile real-world data on the use of the VERAFEYE System in standard of care atrial fibrillation (AF) ablation procedures and left atrial appendage closure (LAAC) procedures.
Conditions
- Atrial Fibrillation
- Left Atrial Appendage Closure
- Atrial Arrhythmia
Interventions
VERAFEYE SystemDevice
VERAFEYE system guidance will be used on all patients undergoing AF ablation and/or LAAC procedures.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Acute procedural success rates during the index procedureTime frame: During the procedure
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.